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Summary
Background:  Pentraxin  3  (PTX3)  is  increased  in  circulating  blood  during  the  acute  stage  of  acute
coronary  syndrome  (ACS).  Therefore,  we  compared  diagnostic  values  of  PTX3  for  ACS  with  those
of biomarkers  for  myocardial  damage,  such  as  troponin  T  (TnT)  and  heart-type  fatty  acid  binding
protein (H-FABP).
Methods  and  results:  Patients  (n  =  87)  undergoing  coronary  angiography  (CAG),  consisting  of  16
ACS and  71  non-ACS  patients  were  enrolled.  Non-ACS  consists  of  12  patients  with  normal  CAG,  30
stable angina  pectoris  (SAP)  patients  controlled  by  medical  treatment,  and  29  SAP  patients  who
required elective  coronary  revascularization  (percutaneous  coronary  intervention  or  coronary
artery bypass  graft).  Age,  gender,  or  prevalence  of  diabetes,  hypertension,  or  smoking  was  not
signiﬁcantly  different  between  ACS  and  non-ACS  groups.  Serum  total,  high-density  lipoprotein,
or low-density  lipoprotein  cholesterol,  or  triglyceride  levels  were  not  signiﬁcantly  different
between  ACS  and  non-ACS.  PTX3  levels  were  not  signiﬁcantly  correlated  with  lipid  proﬁles  or
different between  those  with  and  without  conventional  risk  factors.  Circulating  PTX3,  TnT,  and
H-FABP levels  were  signiﬁcantly  higher  in  ACS  than  non-ACS.  In  receiver-operating  characteristic
(ROC) curves,  area  under  the  curve  (AUC)  values  for  PTX3,  TnT  and  H-FABP  were  0.920,  0.674,
and 0.690,  respectively.  ROC  curves  of  PTX3  (AUC:  0.901),  TnT  (AUC:  0.731),  and  H-FABP  (AUC:
0.633) for  ST-elevation  ACS  were  similar  to  those  for  whole  ACS.  In  a  TnT-negative  subgroup,
the AUC  values  of  PTX3  and  H-FABP  for  ACS  were  0.981  and  0.489,  respectively.
Conclusions:  PTX3  is  a  sensitive
additional  diagnostic  values  whe
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Introduction
Onset  of  acute  coronary  syndrome  (ACS)  involves  rupture
or  erosion  of  atherosclerotic  plaques  in  coronary  arteries.
Although  biomarkers  for  ischemic  myocardial  damage,  such
as  troponin-T  (TnT)  and  heart-type  fatty  acid  binding  pro-
tein  (H-FABP),  have  been  clinically  utilized  to  diagnose  ACS,
diagnostic  sensitivity  and  speciﬁcity  for  ACS,  especially  at
the  earliest  stage,  remain  insufﬁcient.  Pro-inﬂammatory
responses  and  oxidative  stresses,  including  oxidized  low-
density  lipoprotein  (Ox-LDL),  appear  to  play  key  roles  in
atherosclerotic  progression  and  atherosclerotic  plaque  rup-
ture  or  erosion,  by  inducing  cell  apoptosis,  and  production
and  activation  of  matrix  metalloproteinases  (MMPs)  [1,2].
High-sensitivity  C-reactive  protein  (hs-CRP)  is  a  well-known
inﬂammatory  biomarker  which  reﬂects  these  proinﬂamma-
tory  responses  [3,4]. Furthermore,  other  proinﬂammatory
biomarkers,  such  as  interleukin  (IL)-6  and  IL-18,  have  also
been  suggested  as  ACS  biomarkers  [5,6]. In  addition,  N-
terminal  pro-B-type  natriuretic  peptide  (NT-proBNP)  is  also
a  biomarker  for  cardiovascular  disease  risks  including  ACS
[7,8].  Our  previous  studies  have  shown  that  soluble  lectin-
like  oxidized  LDL  receptor-1  (sLOX-1),  a  soluble  protein
corresponding  to  an  Ox-LDL  receptor,  is  also  suggested  as
an  ACS  biomarker  [9—13].
Pentraxin  3  (PTX3),  a  member  of  CRP-like  inﬂammatory
protein  group,  is  abundantly  expressed  in  atherosclerotic
plaques,  as  well  as  in  cardiac  myocytes  [14,15].  Previous
studies  have  shown  that  circulating  PTX3  levels  were  sig-
niﬁcantly  elevated  in  the  acute  stages  of  acute  myocardial
infarction  (AMI)  and  unstable  angina  pectoris  (UAP)  [15,16],
which  are  collectively  termed  as  ACS.  In  addition,  prognos-
tic  values  of  PTX3  for  future  AMI  and  mortality,  in  patients
with  ACS  without  ST  elevation  and  ST  elevation  AMI,  respec-
tively,  have  also  been  demonstrated  [17,18].  As  a  diagnostic
test,  however,  its  diagnostic  sensitivity  and  speciﬁcity  have
not  yet  been  compared  with  other  biomarkers.
In  the  present  study,  therefore,  we  have  examined  the
diagnostic  values  of  PTX3,  comparing  with  those  of  TnT
[19—22]  and  H-FABP  [21—24]  which  are  currently  utilized  to
detect  AMI  in  clinical  practice.
Methods
Patient  samples
We  examined  87  patients,  who  consecutively  underwent
coronary  angiography  (CAG)  at  the  Cardiovascular  Center,
Osaka  Red  Cross  Hospital,  and  whose  circulating  PTX3  levels
were  measured.  ACS  was  deﬁned  as  acute  onset  of  prolonged
chest  pain  or  chest  discomfort  accompanied  by  ST-segment
elevation  or  depression  evolving  into  pathological  Q  waves
or  inverted  T  wave,  as  well  as  emergency  CAG-documented
total  occlusion  or  marked  delayed  ﬁlling  of  a  coronary
artery  as  previously  described  [9—12]. Sixteen  patients  were
diagnosed  with  ACS,  and  71  patients  were  without  ACS  (non-
ACS).  Non-ACS  consists  of  12  patients  without  signiﬁcant
luminal  narrowing  in  CAG,  30  patients  with  medically  con-
trolled  stable  angina,  and  29  patients  with  stable  angina  who
required  elective  percutaneous  coronary  intervention  (PCI)
or  coronary  artery  bypass  graft  surgery  (CABG).  Patients  with
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asospastic  angina,  symptomatic  peripheral  artery  disease
r  stroke  were  excluded  from  this  study.  Informed  consent
as  obtained  from  all  the  participants.  This  study  was  car-
ied  out  in  accordance  with  the  principles  of  the  declaration
f  Helsinki  and  had  been  approved  by  a  local  ethical  com-
ittee.
aboratory  tests
erum  samples  were  collected  from  the  peripheral  venous
lood  during  the  CAG.  In  ACS  cases,  the  mean  time  inter-
al  from  the  symptom  onset  to  the  blood  sampling  was
.8  h.  These  samples  had  been  stored  at  −80 ◦C  until  assays
ere  performed.  Circulating  PTX3  levels  were  measured  by  a
andwich  enzyme-linked  immunosorbent  assay  (ELISA)  which
as  commercially  available  (Alexis,  Lausen,  Switzerland).
evels  of  hs-CRP,  TnT,  and  H-FABP  were  determined  on
he  same  serum  samples  as  those  for  PTX3  by  commer-
ially  available  particle-enhanced  immunonephelometry
Dade  Behringer,  Tokyo,  Japan),  electro-chemiluminescent
mmunoassay  kit  (Roche,  Basel,  Switzerland),  and  ELISA
Marco  Pharmaceutical,  Tokyo,  Japan),  respectively  [9—12].
ll  the  assays  were  carried  out  by  personnel  who  had  no
nowledge  of  the  clinical  diagnosis  of  the  patients.
tatistical  analyses
istribution  of  PTX3,  hs-CRP,  TnT,  and  H-FABP  was  skewed;
herefore,  Wilcoxon/Kruskal—Wallis  test  was  applied  to
xamine  statistically  signiﬁcant  differences.  Statistically
igniﬁcant  differences  in  total  cholesterol,  triglycerides,
igh-density  lipoprotein  (HDL)  cholesterol,  and  LDL  choles-
erol  were  assessed  by  ANOVA.  Statistically  signiﬁcant
orrelations  between  two  parameters  were  evaluated  by
pearman’s  test.  All  the  statistical  analyses  were  carried  out
y  use  of  JMP  IN  (SAS  Institute,  Cary,  NC,  USA).
esults
haracteristics  of  study  subjects
haracteristics  of  the  87  patients  (71  non-ACS  and  16  ACS),
ho  underwent  CAG  and  were  involved  in  this  study,  are
ndicated  in  Table  1.  Age  (p  =  0.541),  gender  (p  =  0.817),  and
revalence  of  conventional  cardiovascular  risk  factors,  such
s  diabetes  (p  =  0.984),  smoking  (p  =  0.947),  and  hyperten-
ion  (p  =  0.248),  were  not  signiﬁcantly  different  between
CS  and  non-ACS  patients.  In  addition,  neither  total  choles-
erol  (p  =  0.086),  triglyceride  (p  =  0.094),  HDL  cholesterol
p  =  0.220),  nor  LDL  cholesterol  (p  =  0.566)  levels  were  sig-
iﬁcantly  different  between  the  ACS  and  non-ACS  groups
Table  1).
TX3  levels  and  conventional  cardiovascular  risk
actorsirculating  PTX3  levels  were  not  signiﬁcantly  different
etween  males  and  females  (median:  0.03  vs.  0.02  ng/mL,
 =  0.618),  or  with  and  without  conventional  risk  factors,
uch  as  diabetes  (median:  0.03  vs.  0.02  ng/mL,  p  =  0.438),
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Table  1  Characteristics  of  study  subjects.
Total  ACS  non-ACS  p-value
Patient  number  87  16  71
Age 66.1  ±  10.5  64.1  ±  13.3  66.0  ±  10.4  0.541
Male gender  (%)  57  (66.3)  11  (68.8)  46  (65.7)  0.817
Diabetes (%)  27  (31.0)  5  (31.3)  22  (31.0)  0.984
Smoking (%)  32  (36.8)  6  (37.5)  26  (36.6)  0.947
Hypertension  (%) 38  (44.2)  5  (31.5)  33  (47.2)  0.248
Total cholesterol  (mg/dL)a 195.0  ±  37.3 179.0  ±  32.6  198.0  ±  37.5  0.086
Triglycerides  (mg/dL)a 136.2  ±  71.5 108.3  ±  28.5 137.6  ±  65.1  0.094
HDL cholesterol  (mg/dL)a 48.0  ±  14.2 44.1  ±  13.0 49.2  ±  14.5 0.220
LDL cholesterol  (mg/dL)a 120.0  ±  34.7 115.4  ±  31.4 121.1  ±  35.7 0.566
PTX3 (pg/mL)b 0.03  (0,  0.16)  0.36  (0.225,  1.39)  0.015  (0,  0.06)  <0.0001
TnT (ng/mL)b 0.01  (0.01,  0.01)  0.025  (0.01,  0.208)  0.01  (0.01,  0.01)  0.0026
H-FABP (ng/mL)b 3.3  (2.6,  5.7)  12.4  (2.9,  105.3)  3.2  (2.6,  4.6)  0.018
ACS, acute coronary syndrome; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PTX3, pentraxin 3; TnT, troponin T; H-FABP,
heart-type fatty acid binding protein.
a Mean ± S.D.
b Median (25th percentile, 75th percentile).
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Figure  1  Comparison  of  circulating  PTX3,  hs-CRP,  TnT,  and  H-FABP  levels  between  ACS  and  non-ACS.  Circulating  PTX3  (panel  A),
TnT (panel  B),  H-FABP  (panel  C),  and  hs-CRP  (panel  D)  levels  are  compared  between  ACS  and  non-ACS.  PTX3,  TnT,  and  H-FABP,  but
not hs-CRP,  levels  were  signiﬁcantly  higher  in  ACS  than  in  non-ACS.  ACS,  acute  coronary  syndrome;  H-FABP,  heart-type  fatty  acid
binding protein;  hs-CRP,  high-sensitivity  C-reactive  protein;  PTX3,  pentraxin  3;  TnT,  troponin  T.
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Figure  2  Correlation  of  circulating  PTX3  with  TnT,  H-FABP,  and  hs-CRP  levels.  Correlation  of  circulating  PTX3  with  TnT  (panel  A),
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rH-FABP (panel  B),  or  hs-CRP  (panel  C)  is  shown.  Circulating  PT
H-FABP, heart-type  fatty  acid  binding  protein;  hs-CRP,  high-sens
smoking  (median:  0.0125  vs.  0.03  ng/mL,  p  =  0.141),  or
hypertension  (median:  0.03  vs.  0.025  ng/mL,  p  =  0.916).  In
addition,  circulating  PTX3  levels  were  not  signiﬁcantly  cor-
related  with  age  (Spearman’s    =  0.0153,  p  =  0.888),  total
cholesterol  (Spearman’s    =  −0.167,  p  =  0.165),  triglyceride
(Spearman’s    =  0.0046,  p  =  0.969),  LDL  cholesterol  (Spear-
man’s    =  0.001,  p  =  0.993),  or  HDL  cholesterol  (Spearman’s
  =  −0.213,  p  =  0.0666)  levels.
PTX3  levels  and  ACS
Peripheral  blood  biomarker  levels  were  compared  between
ACS  and  non-ACS  groups.  As  shown  in  Fig.  1A,  circulat-
ing  PTX3  levels  were  signiﬁcantly  higher  in  ACS  than  in
non-ACS  (median:  0.36  ng/mL  vs.  0.015  ng/mL,  p  <  0.0001).
Serum  TnT  (median:  0.438  vs.  0.0329  ng/mL,  p  =  0.00425,
Fig.  1B)  and  H-FABP  (median:  12.4  vs.  3.3  ng/mL,  p  =  0.0225,
F
l
s
Fd  not  show  signiﬁcant  correlation  with  TnT,  H-FABP  or  hs-CRP.
y  C-reactive  protein;  PTX3,  pentraxin  3;  TnT,  troponin  T.
ig. 1C)  levels  also  were  signiﬁcantly  higher  in  ACS  than  in
on-ACS,  as  previously  reported.  In  contrast,  serum  hs-CRP
evels  were  not  signiﬁcantly  different  between  the  ACS  and
on-ACS  groups  (median  1.71  mg/L  vs.  1.64  mg/L,  p =  0.678,
ig.  1D)  in  our  study  cohort.
orrelation  of  PTX3  with  other  biomarkers
e,  furthermore,  explored  the  correlation  among  these
iomarkers.  Circulating  PTX3  levels  showed  signiﬁcant  cor-
elation  with  TnT  levels  (Spearman’s    =  0.337,  p  =  0.0015,
ig.  2A)  and  H-FABP  (Spearman    =  0.264,  p  =  0.0139,  Fig.  2B)
evels;  however,  their  correlation  with  hs-CRP  levels  was  not
tatistically  signiﬁcant  (Spearman’s    =  0.252,  p  =  0.0588,
ig.  2C).  In  addition,  TnT  and  H-FABP  levels  showed
42  N.  Kume  et  al.
Figure  3  Comparison  of  ROC  curves  for  diagnosis  of  ACS  among  PTX3,  TnT  and  H-FABP.  ROC  curves  demonstrate  that  PTX3  (panel
A) showed  higher  sensitivity  and  speciﬁcity  for  detection  of  ACS  than  TnT  (panel  B)  and  H-HABP  (panel  C).  AUC  values  for  PTX3,
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inT, and  H-FABP  were  0.920,  0.699,  and  0.694,  respectively.  A
eart-type fatty  acid  binding  protein;  PTX3,  pentraxin  3;  ROC,  
lose  correlation  with  each  other  (Spearman’s    =  0.507,
 <  0.0001,  Fig.  2D).
iagnostic  values  of  PTX3  for  ACS
o  compare  the  diagnostic  speciﬁcity  and  sensitivity  of
TX3  for  ACS  with  those  of  TnT  and  hs-CRP,  receiver-
perating  characteristic  (ROC)  curves  for  the  detection  of
CS  were  compared  (Fig.  4).  Sensitivity  and  speciﬁcity  of
TX3  (Fig.  3A)  for  the  diagnosis  of  ACS  appear  to  be  higher
han  those  of  TnT  (Fig.  3B)  and  H-FABP  (Fig.  3C).  Area  under
he  curve  (AUC)  values  for  PTX3,  TnT,  and  H-FABP  were
.920,  0.674,  and  0.690,  respectively.  Diagnostic  values  of
TX3  were  also  evaluated  in  ST-elevation  ACS  (STE-ACS)
lone,  comparing  them  with  those  of  TnT  and  H-FABP,  by
xclusion  of  non-ST-elevation  ACS  (NSTE-ACS)  patients.  The
TE-ACS  subgroup  consisted  of  12  patients.  As  shown  in
ig.  4,  ROC  curves  of  PTX3,  TnT,  and  H-FABP  in  the  STE-ACS
ppeared  to  be  similar  to  those  in  the  whole  ACS  population
Fig.  3).  AUC  values  of  PTX3,  TnT,  and  H-FABP  for  detection
f  STE-ACS  were  0.901,  0.731,  and  0.633,  respectively.
iagnostic  values  of  PTX3  for  TnT-negative  ACS
ecause  TnT  currently  is  considered  as  a  golden  standard
iomarker  for  the  diagnosis  of  AMI  in  clinical  practice,  ROC
urves  were  also  evaluated  in  the  TnT-negative  (less  than
.03  ng/mL)  subpopulation.  Numbers  of  TnT-negative  sub-
ects  in  the  non-ACS  group  and  the  ACS  group  were  58  and  8,
espectively.  The  ROC  curves  in  the  TnT-negative  subgroup
re  shown  in  Fig.  5.  The  AUC  values  of  PTX3  (Fig.  5A)  and
-FABP  (Fig.  5B)  for  ACS  were  0.981  and  0.489,  respectively,
n  the  TnT-negative  subgroup.  ROC  curves  of  PTX3  for  ACS
ppeared  similar  between  the  whole  population  (Fig.  3A)
nd  the  TnT-negative  subgroup  (Fig.  5A),  indicating  the
dditional  diagnostic  values  of  PTX3  when  measured  in  com-
ination  with  TnT.  In  contrast,  the  ROC  curves  of  H-FABP  for
CS  in  the  TnT-negative  subgroup  showed  much  lower  diag-
c
t
H
ccute  coronary  syndrome;  AUC,  area  under  the  curve;  H-FABP,
iver-operating  characteristic;  TnT,  troponin  T.
ostic  sensitivity  and  speciﬁcity  (AUC:  0.489,  Fig.  5B)  when
ompared  with  the  whole  population  (AUC:  0.633,  Fig.  3B).
iscussion
nset  of  ACS  appears  to  involve  rupture  or  erosion  of
ulnerable  atheromatous  plaques  with  thin  ﬁbrous  caps,
arge  lipid  cores,  and  inﬁltration  of  abundant  macrophages
nd  T-lymphocytes.  Pro-inﬂammatory  and  oxidative  stresses
ppear  to  play  key  roles  in  the  formation  of  erosion-  and
upture-prone  vulnerable  plaques,  by  apoptosis  of  vascu-
ar  endothelial  and  smooth  muscle  cells  and  macrophages,
roduction  and  activation  of  matrix  metalloproteinases,  as
ell  as  induced  expression  of  chemokines  and  endothelial-
eukocyte  adhesion  molecules.  PTX3  is  one  of  the  molecules
hat  are  expressed  in  atherosclerotic  plaques  and  suggested
o  be  involved  in  plaque  vulnerability.  Previous  reports
howed  that  circulating  PTX3  levels  were  elevated  in  AMI
15]  and  in  UAP  [16]; however,  diagnostic  values  of  this
iomarker  for  AMI  or  UAP  have  not  been  fully  clariﬁed.  We,
herefore,  have  explored  diagnostic  sensitivity  and  speci-
city  of  PTX3  for  ACS,  comparing  with  other  biomarkers.
he  present  results  show  that  PTX3  appears  to  be  superior
o  TnT  and  H-FABP  in  early  diagnosis  of  ACS.  In  addition,
irculating  PTX3  levels  do  not  show  any  signiﬁcant  differ-
nces  between  presence  and  absence  of  conventional  risk
actors,  such  as  diabetes,  smoking,  and  hypertension.  Fur-
hermore,  PTX3  shows  no  signiﬁcant  correlation  with  lipid
roﬁles,  TnT,  H-FABP,  or  another  inﬂammatory  biomarker  hs-
RP,  thus  indicating  that  PTX3  is  an  independent  biomarker.
PTX3  is  abundantly  expressed  in  atherosclerotic  plaques
14];  therefore,  vulnerable  or  ruptured  atherosclerotic
laques  may  be  major  sources  of  increased  circulating  PTX3
evels.  In  addition,  circulating  PTX3  may  also  derive  from
njured  myocardium,  because  PTX3  is  also  expressed  by
ardiomyocytes.  In  fact,  PTX3  showed  signiﬁcant  correla-
ion  with  biomarkers  for  cardiac  damage,  such  as  TnT  and
-FABP  in  this  study.  Although  a  previous  study  has  indi-
ated  time-dependent  changes  in  circulating  PTX  levels  in
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Figure  4  Comparison  of  ROC  curves  for  diagnosis  of  ST  elevation-ACS  among  PTX3,  TnT,  and  H-FABP.  ROC  curves  demonstrate  that
PTX3 (panel  A)  showed  higher  sensitivity  and  speciﬁcity  for  detection  of  ACS  than  TnT  (panel  B)  and  H-FABP  (panel  C).  AUC  values
ctive
3;  RO
o
i
s
h
ﬁ
a
t
tfor PTX3,  TnT,  and  H-FABP  were  0.901,  0.731,  and  0.633,  respe
H-FABP, heart-type  fatty  acid  binding  protein;  PTX3,  pentraxin  
acute  stages  of  AMI,  comparing  those  in  hs-CRP  [15], time-
dependent  changes  in  PTX3  levels  during  acute  stages  of  ACS
have  not  yet  been  compared  with  those  in  biomarkers  of
cardiac  damage,  such  as  TnT  and  H-FABP.  Therefore,  molec-
ular  mechanisms  involved  in  elevated  circulating  levels  of
PTX3  in  ACS  remain  to  be  fully  elucidated  in  the  future,  by
experiments  with  suitable  animal  models  in  vivo.
In  any  case,  the  present  report  has  compared,  for  the
ﬁrst  time,  the  diagnostic  sensitivity  and  speciﬁcity  of  PTX3
for  ACS  with  other  biomarkers,  such  as  TnT  and  H-FABP.  ROC
curves  clearly  indicated  that  PTX3  showed  higher  sensitiv-
ity  and  speciﬁcity,  than  TnT  and  H-FABP,  for  the  diagnosis
p
d
n
m
Figure  5  Comparison  of  ROC  curves  for  diagnosis  of  ACS  between  PT
PTX3 (panel  A)  and  H-FABP  (panel  B)  in  the  TnT-negative  (<0.03  ng/m
consisted of  8  ACS  and  58  non-ACS  subjects.  ROC  curves  similarly  sho
for detection  of  ACS  than  H-FABP  (panel  B).  AUC  values  for  PTX3  and  H
respectively.  ROC  curves  for  PTX3  appear  to  be  similar  between  the
(panel A).  ACS,  acute  coronary  syndrome;  AUC,  area  under  the  curve;
3; ROC,  receiver-operating  characteristic;  TnT,  troponin  T.ly.  ACS,  acute  coronary  syndrome;  AUC,  area  under  the  curve;
C,  receiver-operating  characteristic;  TnT,  troponin  T.
f  ACS,  as  well  as  STE-ACS  or  AMI.  Cardiac  TnT  currently
s  considered  as  a  golden  standard  biomarker  for  diagno-
is  of  AMI  and  utilized  in  clinical  practice;  therefore,  we
ave  further  compared  the  diagnostic  sensitivity  and  speci-
city  of  PTX3,  as  well  as  H-FABP,  in  the  whole  subjects
nd  the  TnT-negative  subpopulation  in  this  study.  Diagnos-
ic  speciﬁcity  and  sensitivity  of  PTX3  were  similar  between
he  whole  ACS  population  and  the  TnT-negative  ACS  sub-
opulation,  indicating  that  PTX3  would  provide  additional
iagnostic  information  for  ACS,  when  measured  in  combi-
ation  with  TnT.  In  contrast,  H-FABP  appeared  to  exhibit
uch  less  diagnostic  values  for  ACS  in  the  TnT-negative  sub-
X3  and  H-FABP  in  a  TnT-negative  subpopulation.  ROC  curves  for
L)  subpopulation  are  shown.  The  TnT-negative  subpopulation
w  that  PTX3  (panel  A)  exhibits  higher  sensitivity  and  speciﬁcity
-FABP  in  the  TnT-negative  subpopulation  were  0.981  and  0.489,
 total  population  (Fig.  4A)  and  the  TnT-negative  subpopulation
 H-FABP,  heart-type  fatty  acid  binding  protein;  PTX3,  pentraxin
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opulation  when  compared  with  the  whole  population,  thus
ndicating  its  strong  dependency  upon  TnT  and  less  diagnos-
ic  values  when  measured  in  combination  with  TnT.
Recently,  high-sensitivity  troponins  T  and  I  have  been
hown  to  detect  AMI  in  the  early  stages  [25,26].  In  these
arge-scale  international  multicenter  studies,  the  ROC  curve
f  the  conventional  TnT  to  diagnose  AMI  appeared  similar  to
urs,  thus  indicating  the  appropriateness  of  our  patient  sam-
les  although  the  size  was  small.  It  should  be  tested,  in  the
uture,  whether  PTX3  has  incremental  values  to  diagnose
CS  or  AMI  in  the  early  stages,  in  addition  to  these  sensitive
ssays  for  troponins.
In  conclusion,  the  present  study  clearly  demonstrates
hat  diagnostic  sensitivity  and  speciﬁcity  of  PTX3  for  ACS,
n  the  early  stage,  appear  to  be  superior  to  those  of  TnT
nd  H-FABP,  thus,  indicating  that  PTX3  is  one  of  the  use-
ul  biomarkers  for  detecting  ACS,  alone  or  in  combination
ith  other  biomarkers  including  TnT.  In  addition,  a  previous
tudy  has  shown  that  PTX3  can  predict  3-month  mortality
fter  AMI  [18]; therefore,  PTX3  may  also  be  useful  for  risk
tratiﬁcation  and  prediction  of  ACS  recurrence  after  ACS  or
rediction  of  ACS  in  stable  coronary  artery  disease  patients,
s  well  as  long-term  future  risk  for  cardiovascular  events  in
ealthy  subjects.  These  points  should  further  be  explored
n  prospective  multicenter  studies  with  large  sample  sizes
n  the  future.
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